作者：肖毅频1，钟晓华1，熊璐琪2，陈超1，凌旭坤1，胡琛1

单位：1.惠州市中心人民医院 胃肠外科，广东 惠州 516001； 2.惠州市中心人民医院 药学部，广东 惠州 516001

Authors:  XIAO Yipin1, ZHONG Xiaohua1, XIONG Luqi2, CHEN Chao1, LING Xukun1, HU Chen1

Unit:  1.Department of Gastrointestinal Surgery, Huizhou Municipal Central Hospital, Huizhou 516001, Guangdong, China; 2.Department of Pharmacy, Huizhou Municipal Central Hospital, Huizhou 516001, Guangdong, China

摘要：

目的  探讨FOLFIRI方案的时辰化疗对比常规化疗治疗复发转移性结直肠癌患者的近期疗效和不良反应。方法  收集我院2015年9月至2017年9月收治的80例复发转移性结直肠癌患者,均采用FOLFIRI方案化疗,随机分成时辰化疗组和常规化疗组(各组40人),化疗2个周期后评估患者的有效率、疾病控制率及主要不良反应的发生率。结果  对比常规化疗组,时辰化疗组的有效率及疾病控制率更高,但结果无显著差异。时辰化疗组的白细胞及中性粒细胞减少发生率、贫血发生率、恶心呕吐发生率显著低于常规化疗组(P<0.05),而其他毒副作用发生率无显著差异。结论  FOLFIRI方案的时辰化疗近期疗效略优于常规化疗,但主要毒副作用显著减轻,可作为复发转移性结直肠癌治疗的替代方案。

关键词： 时辰化疗; 结直肠癌; FOLFIRI; 近期疗效; 不良反应

Abstract：

Objective  To explore the short-term effects and toxicities of chronochemotherapy compared with conventional chemotherapy with FOLFIRI regimen for patients with recurrent and/or metastatic colorectal cancer. Methods  From September 2015 to September 2017, 80 patients with recurrent and/or metastatic colorectal cancer were prospectively collected. All patients undergoing chemotherapy with FOLFIRI regimen were randomly divided into chronochemotherapy group (40 patients) and conventional chemotherapy group (40 patients). The effective rate, disease control rate and incidence of main adverse reaction were evaluated. Results  As compared with conventional chemotherapy group, the effective rate and disease control rate in chronochemotherapy group were improved, but there were no significant differences. Besides, the incidence of leucopenia and neutropenia, anemia, nausea and vomiting were significantly decreased (P<0.05), with no significant difference observed for other main adverse reactions. Conclusions  Chronochemotherapy with FOLFIRI regimen has better short-term effects, with decreased incidence of main adverse reaction compared to conventional chemotherapy. As a result, it can be an optimal replacement measure for such patients.

Key Words:  Chronochemotherapy; Colorectal cancer; FOLFIRI; Short-term effects; Adverse effect